October #64 : My, What a Big Trial IL-2 Has! Will It Work?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Stephen Gendin

Be Very Afraid

The CD4 Solution?

The Boys in the Band

Bare Witness

The March

My, What a Big Trial IL-2 Has! Will It Work?

AIDSplotation or Art?

Refugee All-Stars

Drive-By Shopping

Upward Mobility

S.O.S

NEG/POS

Take Five

POZ Picks

The Medium Is The Message

A Conference Of Their Own

Milestones

Cutting Class

Last Word

It Takes A Village Voice

Conference of the Century

Stop and Start

Sit Up, Sit Down?

Too Much Information

Sex RX

Talking Tipranavir

Shelf Life

The In Crowd

Herb Of The Month

He Died Of Old AIDS

10.8.88: Old Flames



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October 2000

My, What a Big Trial IL-2 Has! Will It Work?

When NIAID launched its five-year ESPRIT megatrial of IL-2 plus HAART vs. HAA

When NIAID launched its five-year ESPRIT megatrial of IL-2 plus HAART vs. HAART alone, many hailed it as a long-overdue step toward funding much-needed immune-based-therapy research. But critics raised troubling questions ranging from dosage to bang-for-buck and more. Consider:

Cost. Why spend so much on IL-2 when other promising but understudied immune-based therapies -- everything from therapeutic vaccines to the hormone DHEA to herbal combinations -- go begging?

Design. Will the varying cycle lengths (after six months the fixed schedule gives way to physician discretion) make data analysis impossible? And is five years long enough to see real differences in disease progression between those on HAART alone and those who spike it with IL-2?

Practicality. ESPRIT will require 2,000 HIVers with CD4s above 300 to self-inject, for five days every eight weeks, high-dose IL-2 plus down their tricky HAART regimens. Will enough healthy HIVers sign on to this rigorous, side effect-prone therapy to fully enroll the trial? The University of Colorado's Robert Schooley, MD, says, "You could be holding your breath for a long, long time."

Missed Opportunities. The trial's large size could yield important knowledge about new cell tests that might better measure immune changes, so why aren't samples of all participants' cells (instead of a limited number) being stored? Brenda Lein, director of Project Immune Restoration at Project Inform, says, "ESPRIT is useless in terms of answering the question of immune markers."

But NIAID official Jack Killen defends the trial. "It's taking big risks," he acknowledges, "but it's an important study that's been through an enormous amount of scrutiny."




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    soy_Ric
    Rochester
    New York


    Deelight4u
    BROOKLYN
    New York


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.